• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    High Purity New England Bolsters Biopharma Solutions Services

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    Covectra Introduces Next-Gen Serialization Solution
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    C2 Pharma Completes Multiple Regulatory Filings

    Bormioli Opens New Glass Research Center

    Why Increasing Solubility May Not Improve Bioavailability - In Vitro Predictions
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing

    PwC Joins Medicines Manufacturing Innovation Centre
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    CrownBio & JSR Life Sciences Partner with Cambridge Quantum Computing

    Stevanato Group Launches AI Platform
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Emergent BioSolutions

    Baxter BioPharma Solutions

    Almac Group

    Adare Pharma Solutions

    Alcami
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    test company saurabh

    Almac Group

    Aphena Pharma Solutions

    Emergent BioSolutions

    PCI Pharma Services
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Decentralized Trials Fuel AI Revolution in Clinical Research

    The life sciences industry is giving clinical a full makeover, dramatically improving how new therapeutics are developed.

    Decentralized Trials Fuel AI Revolution in Clinical Research
    Decentralized Trials Fuel AI Revolution in Clinical Research
    Figure 1. This heatmap snapshot from mid-March plots the incidence of COVID-19 from initial emergence. Color gradient ranges from yellow to red denoting COVID-19 concentrations by region. (Image Copyright 2020. Medable, Inc.)
    Related CONTENT
    • ACG Launches ACG Laboratories
    • Vetter continues its successful performance at the 2021 CMO Leadership Awards
    • Molecular Templates, BMS Enter Strategic Research Pact
    • Masy BioServices Expands Green Initiative
    • Syntegon Validates First AI-equipped Visual Inspection System
    Nick Moss, Vice President of Analytics and Machine Learning, Medable11.17.20
    For decades, improving clinical trial outcomes has focused on reducing time and cost. That focus, and the challenges of a global pandemic, has ignited the digitization of the clinical trial life cycle. Decentralized Clinical Trials (DCTs), which put the patient at the center of the trial experience and incorporate digital technologies, and artificial intelligence (AI) are combining to transform clinical research. Organizations are marrying DCT methodologies with AI in innovative ways to reshape workflows across the clinical lifecycle, from trial design and patient recruitment to evidence generation—and are seeing striking decreases in both the time and cost of clinical studies.

    Today, there are at least 25,000 clinical trials offering a form of open source data. With the right analytical tools and AI, the industry can take advantage of this rich data to optimize patient recruitment, increase patient retention, reduce timelines, and maximize study results in future trials. AI can also expedite target validation, trial design, and patient identification.

    DCTs can also reduce time and cost of clinical studies by expanding patient access and retention as a result of allowing patients to participate safely and conveniently in their homes. DCTs also minimize geographic, transportation, costs, and other barriers that can improve the diversity of participants. The net effect is an improvement in data quality as site-based transcription is eliminated plus an increase in efficiency for patients, sites, and study teams. Together, AI and DCTs can be a powerful force.

    It is time to deploy AI with purpose. To do so, AI engines require more than just mountains of data. To provide accuracy, the data needs to be closely representative of the target population. Traditional clinical trials, as has been highly publicized in recent months, are often comprised of participants from urban areas and are predominantly white. DCTs fuel AI engines since they inherently capture massive real-world, real-time data from diverse patient populations more inclusive of the diverse world in which we live. By combining both innovations, companies will improve three crucial areas of clinical trials: trial design, patient recruitment, and evidence generation.

    Customized Trial Design that Drives Results
    The application of AI and machine learning can significantly improve trial design in a host of ways—from identifying the ideal sample size to what data should be experimentally generated, to target validation and trial execution. Industrywide efforts to target underlying biological pathways of disease also drive a need for more precise patient screening protocols and trial design.1 Machine learning, a primary method of AI that can consume vast data sets and utilize complex algorithms to learn from it, finds patterns and makes predictions about future state. To advance the development of these methods, organizations like Machine Learning Ledger Orchestration for Drug Discovery (MELLODY) and Machine Learning for Pharmaceutical Discovery and Synthesis (MLPDS) were formed.2

    Vaccines provide a powerful example of AI’s impact on trial design, especially in light of the race for a COVID-19 vaccine. As the vaccines for COVID-19 progress to late stages, AI can help identify signatures of vaccine response. Similar to the adoption of viral load as a surrogate endpoint, which drastically reduced HIV trials from four years to six months, understanding immune signatures of vaccine response can accelerate vaccine trials. Recognizing the critical role of adjuvants in the efficacy of vaccines, a 2019 malaria vaccine study by a group from U.S. Army Medical Research and the Walter Reed Army Institute demonstrated that the combination of machine learning with immune-profiling could most likely identify adjuvant-specific immune responses that can serve to inform decisions on adjuvant selection.3 The method can also enhance vaccine safety by providing valuable insight regarding which immune profiles are associated with reactogenicity.4

    In addition to improving safety and efficacy, machine learning can also expedite the development of new vaccines, as evidenced by a 2016 collaborative effort of the Georgia Institute of Technology, Emory University, and the Centers for Disease Control and Prevention.5 The group utilized DAMIP, a machine learning method, to predict the ability of a vaccine to provide effective immunity within one week of administration. More recently, a group at the University of Michigan employed Vaxign (reverse vaccinology tool) and Vaxign-ML machine learning tool to identify the most appropriate targets for a COVID-19 vaccine.6

    Not only has machine learning been deployed in other vaccine trials to understand critical success factors for COVID-19 vaccine trials, it has also been employed to identify sites with non-COVID-19 trials that would benefit most from decentralization. For example, Medable’s data science and digital trial design teams have been tracking the spread of COVID-19 to understand the impact on clinical trials worldwide. The heatmap (Figure 1) shows the proximity of active oncology study sites to COVID-19 hotspots in the U.S. Combining these data with the fact that many people remain undiagnosed, reinforces the need to enable the continuation of trials remotely, especially for vulnerable patients.

    This data has proven essential to proper planning and COVID mitigation. Machine learning has even predicted future outbreaks, providing key insight to which future trials and sites would be most impacted. Such endeavors directly reduce the barriers, time, and cost of trials. Sponsors are finding considerable value in this innovation. One sponsor commented, “the COVID-19 predictive analytics have enabled us to optimize our feasibility process while ensuring the safety of participants and avoiding delays. The ability to keep pushing forward during a pandemic on behalf of cancer patients everywhere has been invaluable.”

    Expediting the Speed and Diversity of Patient Recruitment
    Patient recruitment remains one of the largest obstacles in drug development. Broad marketing campaigns through avenues like social media have proven expensive and largely ineffective since it is nearly impossible to identify participants that meet clinical criteria at the right time and in the right place. For rare diseases specifically, it is difficult to meet minimum patient enrollment targets within specified timeframes.

    The diversity of trial participants is also a challenge that has generated a significant effort in the industry. Currently, trials do not adequately represent the population with respect to gender, race or ethnicity and many in the industry are initiating efforts to address the problem. For example, Nature published a 2018 study showing that while African Americans comprise 13% of the U.S. population, they only make up 5% of clinical trial participants.7

    The combination of AI and DCTs is key to overcoming the bias challenge since together; they can advance the identification, enrollment and participation of underrepresented groups by removing barriers such as selection bias, geography, transportation, and more. In addition to ensuring diversity of participants, AI can better identify candidates who are most likely to respond to the intervention and even project which patients are least likely to drop out. Some organizations are using advanced neural networks and Bayesian algorithm powered tools to find those candidates—the needle in the haystack.8

    Similarly, many interventional studies require a time-sensitive clinical state that can be difficult to forecast and short in duration. For example, there are critical windows in both Alzheimer’s disease and COVID-19 during which patients are suited for participation in trials. It can be nearly impossible for patients, and even sometimes their primary physician, to know when this window is open. AI methods employing probabilistic models can identify patients in advance of the window. Machine learning applied to clinical data, like that maintained in electronic health records (EHRs), can identify regions and individuals with higher pre-recruitment probability for screening success.

    A research group at Mount Sinai Hospital in New York applied an unsupervised deep learning method to EHR data of approximately 700,000 patients to determine patient representations that provide enhanced clinical predictions.9 The model, dubbed DeepPatient, tested over 76,000 patients, encompassing 78 diseases. It predicted future diseases from cancer to schizophrenia, one of the most challenging diagnoses. DeepPatient held consistently better results than other models. AI and machine learning applications like those leveraged in this project have laid the groundwork to identify research participants at the most critical clinical juncture.

    AI allows trial managers to identify patients faster and easier while reducing the rate of screen failures. Once potential participants are identified, the use of DCTs removes geographical and transportation barriers to screening and participation, resulting in improved speed, retention and diversity of recruitment.

    Real-Time, Real-World: Enhancing Data Quality in Evidence Generation
    Decentralized clinical trials require digital avenues for evidence generation in ways that traditional clinical trials do not. Evaluating the effects of an intervention requires digital endpoints as well as systems that can autonomously interpret physiologic data to detect side effects and monitor patient safety. Therefore, DCTs collect more data that require efficient and accurate analysis and management. AI can discriminate signal from noise and plays a critical role in the development of digital biomarkers.

    It is widely known that machine learning-generated biomarkers from preclinical datasets are crucial to drug discovery. In 2017, the Federal Drug Administration approved pembrolizumab for cancers with a certain genetic biomarker.10 This milestone marked the inaugural tissue agnostic approval of a treatment based on a patient’s biomarker status as opposed to tumor histology. Identification of new preclinical biomarkers can lead to more tissue-agnostic therapies, expediting treatments for multiple disease types.

    Organizations are now developing cloud-based machine learning systems to identify new digital biomarkers. For instance, Medable is using machine learning-based informatics to convert time series signals into a set of histogram signatures that can be used with various supervised and semi-supervised learning methods to create biomarkers. These informatics can also be used for patient identification, feasibility, and data source extraction. Data can be ingested from smartphone sensors, surveys, devices, lab data and more. For instance, gait stability has been monitored in cancer patients and detected fatigue and cognition levels. It is highly accurate and reliable but also has a user-friendly interface with data visualization.

    New machine learning-based informatics provide users varying levels of expertise with low-level and high-level interfaces. It is not strictly required to be a data scientist in order to perform complex data preparation operations and to create and train highly accurate models. Biomarker identification of extends to a multitude of disease categories. Its ability to monitor patient data in real-time provides has the promise to increase measures of patient safety, ensuring accurate reporting of outcomes in a highly scalable manner.

    The value of digital biomarkers stretches beyond indicators of disease to applications in digital therapeutics. Digital therapeutics can shape patient behavior and treat various conditions through digital technologies.11 Using machine learning and other AI approaches with digital therapeutics to monitor and predict data of patient symptomatology can create digital biomarkers,11 resulting in a feedback loop which lends itself to precision medicine.12 DCTs provide for a much broader application of this method, culminating in voluminous data that makes the AI models even smarter.

    In the trial setting, digital biomarkers can predict treatment response from a digital behavioral intervention at the participant level.13 The combination of AI and digital therapeutics also enable enhanced real-time clinical measurements without being compromised by the bias of patient recall.14 In the health care delivery setting, AI and digital therapeutics are essentially a medical device, enabling greater automation and less costly population health management. In addition to monitoring patient symptoms and predicting outcomes, they allow for dynamic adaptation to individual needs, goals, and lifestyles through course correction—particularly important for patients in rural or underserved areas.15

    The Marriage of AI and DCTs Offers Clinical Potential
    At no time has the wisdom of Plato been more evident where necessity is the mother of invention, and now adoption. The current pandemic has driven the fastest adoption of technology and innovation in clinical trial history, and the power of AI married with the vast data available through DCTs makes for a fruitful relationship, particularly in trial design, patient recruitment, and evidence generation. Leveraging AI and DCTs has become a fundamental imperative to developing safe therapies as fast as possible. AI’s continued maturation will expand its use across all stages of the patient journey, and ultimately lead to incredible breakthroughs in personalized medicine to sure cancers and rare diseases.16 

    References
    1. Gerlovin, L., Bonet, B., Kambo, I., and Ricciardi, G. The Expanding Role of Artificial Intelligence. Clinical Leader, June 9, 2020. See full resource here.
    2. Ibid.
    3. Chaudhury, S. Duncan, E.H., Tanmaya, A., Dutta S., Spring M.D., Leitner, W. W., & Bergmann-Leitner, E.S. (2020) Combining immunoprofiling with machine learning to assess the effects of adjuvant formulation on human vaccine-induced immunity, Human Vaccines & Immunotherapeutics, 16:2, 400-411. See full resource here.
    4. Ibid.
    5. Lee, H.I., Nakaya, F.Y., Querec, T.D., Burel. G., Pietz, F.H., Benecke, B.A., & Pulendran, B. (2016) Machine Learning for Predicting Vaccine Immunogenicity. INFORMS Journal on Applied Analytics. 46:5, 368-390. See full resource here.
    6. Ong, E., Wong, M. U., Huffman, A., & He, Y. (2020). COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning. bioRxiv : the preprint server for biology, 2020.03.20.000141. See full resource here.
    7. Gerlovin, et al. Expanding Role.
    8. Diversifying clinical trials. Nat Med 24, 1779 (2018). https://doi.org/10.1038/s41591-018-0303-4
    9. Miotto, R., Li, L., Kidd, B. A., & Dudley, J. T. (2016). Deep Patient: An Unsupervised Representation to Predict the Future of Patients from the Electronic Health Records. Scientific reports, 6, 26094. See full resource here.
    10. Boyiadzis, M. M., Kirkwood, J. M., Marshall, J. L., Pritchard, C. C., Azad, N. S., & Gulley, J. L. (2018). Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. Journal for immunotherapy of cancer, 6(1), 35. See full resource here.
    11. Palanica, A., Docktor, M. J., Lieberman, M., & Fossat, Y. (2020). The Need for Artificial Intelligence in Digital Therapeutics. Digital biomarkers, 4(1), 21–25. See full resource here.
    12. Guthrie NL, Carpenter J, Edwards KL, et al. (2019). Emergence of digital biomarkers to predict and modify treatment efficacy: machine learning study. BMJ Open, 9:e030710. See full resource here.
    13. Palanica, et al. Digital Therapeutics.
    14. Guthrie, et al. Digital Biomarkers.
    15. Palanica, et al. Digital Therapeutics.
    16. Ibid.
    17. Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., Li, B., Madabhushi, A., Shah, P., Spitzer, M., & Zhao, S. (2019). Applications of machine learning in drug discovery and development. Nature reviews. Drug discovery, 18(6), 463–477. See full resource here.

    Nick Moss is a computer scientist who has been passionate about data science and machine learning for over 10 years. He previously worked in finance and investment banking, creating automated stock trading and big data systems and has also worked in high-performance computing on some of the largest supercomputers in the world. At Medable, Nick leads the data science team to create innovative and scalable technological solutions to promote increased efficiency in clinical trials. He can be reached at nick@medable.com.
    Related Searches
    • Clinical Trials
    • Information Technology
    • R&D
    Suggested For You
    ACG Launches ACG Laboratories ACG Launches ACG Laboratories
    Vetter continues its successful performance at the 2021 CMO Leadership Awards Vetter continues its successful performance at the 2021 CMO Leadership Awards
    Molecular Templates, BMS Enter Strategic Research Pact Molecular Templates, BMS Enter Strategic Research Pact
    Masy BioServices Expands Green Initiative Masy BioServices Expands Green Initiative
    Syntegon Validates First AI-equipped Visual Inspection System Syntegon Validates First AI-equipped Visual Inspection System
    Novartis Invests in Credence MedSystems Novartis Invests in Credence MedSystems
    X-Chem Acquires IntelliSyn and AviSyn X-Chem Acquires IntelliSyn and AviSyn
    Improving Product Profitability Improving Product Profitability
    Global Biosciences Co. Selects ValGenesis VLMS  Global Biosciences Co. Selects ValGenesis VLMS
    Chemical Development Chemical Development
    Container Closure Integrity and Stability Testing for Rigid Containers Container Closure Integrity and Stability Testing for Rigid Containers
    Clinical Development Clinical Development
    Genezen Laboratories Receives Growth Equity Investment Genezen Laboratories Receives Growth Equity Investment
    Passage Bio Invests in Gene Therapy Manufacturing R&D Site Passage Bio Invests in Gene Therapy Manufacturing R&D Site
    Evotec, BMS Advance Targeted Protein Degradation Projects Evotec, BMS Advance Targeted Protein Degradation Projects

    Related Features

    • Analytical Services | Information Technology | Laboratory Testing
      Business Intelligence For (and From) the Lab

      Business Intelligence For (and From) the Lab

      How a digital ecosystem can harness the most data-rich environment in the CDMO.
      Bob Voelkner, VP Sales and Marketing, LabVantage 01.27.21

    • Clinical Trials | Information Technology
      The Role of Electronic Monitoring in Maintaining Medication Adherence

      The Role of Electronic Monitoring in Maintaining Medication Adherence

      Digital solutions offer hope to get patients to take their medications properly.
      Bernard Vrijens, Scientific Lead, AARDEX Group 10.14.20

    • Information Technology
      You Need Solutions, Digitization is the Answer

      You Need Solutions, Digitization is the Answer

      Cloud technology helps today’s contract manufacturers be agile, transparent and efficient.
      Brian Curran, Senior Vice President of Strategic Growth, MasterControl 10.14.20


    • Drug Development | Drug Discovery | R&D
      R&D Outsourcing Trends

      R&D Outsourcing Trends

      Highly specialized drug products and capacity needs drive increased reliance on contract service providers.
      Kristin Brooks, Managing Editor, Contract Pharma 10.14.20

    • Information Technology
      Five Ways to Enhance Clinical Operational Efficiencies Utilizing AI

      Five Ways to Enhance Clinical Operational Efficiencies Utilizing AI

      The proven promise and huge potential of using AI and ML to accelerate drug discovery.
      Lucas Glass, Gary Shorter, and Rajneesh Patil, IQVIA 11.20.19

    • Clinical Trials
      Gene Therapy Trials

      Gene Therapy Trials

      Applications and the limitations of real-world data.
      Karen Ooms, Executive Vice President and Head of Statistics, Quanticate 09.16.19


    • Information Technology
      A Brave New World of Data Integrity

      A Brave New World of Data Integrity

      How modern CMOs are keeping up with stringent regulatory guidelines by embracing advanced laboratory information systems.
      Bob Voelkner, VP Sales and Marketing, LabVantage 06.13.19

    • Clinical Trials | Information Technology
      The New Horizon: Metaprise Analytics in Life Sciences

      The New Horizon: Metaprise Analytics in Life Sciences

      Going beyond enterprise analytics to metaprise analytics—patient-centric systems that create a data driven trial team.
      Michelle Longmire, MD, CEO and Founder, Medable 05.07.19

    • Information Technology
      The Manufacturing Revolution In Medicine

      The Manufacturing Revolution In Medicine

      Real-time data insights help both pharma companies and contract manufacturers meet regulatory requirements while ensuring high production standards.
      Petter Moree, OSIsoft, LLC 05.07.19


    • Clinical Trials
      Clinical Trial Feasibility

      Clinical Trial Feasibility

      How to reduce late-stage trial risk with feasibility analysis
      Alan Scott and Denis McMillan, PAREXEL International 04.05.19

    • Clinical Trial Materials | Clinical Trials | Supply Chain
      Optimizing Clinical Supply Management

      Optimizing Clinical Supply Management

      IRT system design strategies to help life science companies cut drug wastage across clinical programs.
      Bart Nicholson, Director of Customer Success for IRT, CRF Bracket 04.05.19

    • Information Technology
      Industry 4.0 in the Pharma Industry

      Industry 4.0 in the Pharma Industry

      Digitization is not a single-handed project.
      Dr. Christian Hanisch, Project Manager Industry 4.0 Pharma, Bosch Packaging Technology 03.06.19


    • Information Technology
      Digitization: Pharma 4.0

      Digitization: Pharma 4.0

      A look at how technology is impacting the pharma industry
      Fatih Kaya and Gerald Buerkle, Vetter Pharma 01.25.19

    • Information Technology
      FDA & Data Integrity

      FDA & Data Integrity

      FDA Publishes Final Guidance on Data Integrity
      Robert Marohn, Director of Quality Business Systems, Kite Pharmaceutical 01.25.19

    • Information Technology | Serialization | Supply Chain
      Serialization Compliance

      Serialization Compliance

      Automated data controls during packaging help improve compliance.
      Miguel Pitarch, Executive Director, Global Serialization, Bristol-Myers Squibb & the Bristol-Myers Squibb Serialization Team 11.13.18

    Trending
    • Catalent Acquires Delphi Genetics
    • Inside A Vaccine Trial
    • Pfizer Selects Seven Bridges To Support RNA Sequencing Data
    • Pfizer Partners With Medicines Manufacturing Innovation Center
    • ICON Acquires Medpass
    Breaking News
    • High Purity New England Bolsters Biopharma Solutions Services
    • AMRI Contributes to Efforts to Increase COVID-19 Vax Supply
    • CatSci Opens New Site in UK
    • Pfizer Partners with Medicines Manufacturing Innovation Center
    • Covectra Introduces Next-Gen Serialization Solution
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    New FDA Traceability Rule Appears to Omit Dietary Supplement Manufacturers
    Clinical Trial Finds Metabolic Benefits for Polyphenols Formula
    JRF Technology Debuts Elderberry Oral Film Strip
    Coatings World

    Latest Breaking News From Coatings World

    Universal Display Corporation, PPG Expand Global Production of UniversalPHOLED Materials
    OQ Chemicals Increases Carboxylic Acids, Esters Prices
    Sensory Analytics Announces Issuance of Broad New Patent Covering Coating Thickness Measurement
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Japan to Lead APAC Assisted Reproductive Technology Devices Market
    Portescap Slotless Brushless DC Motors Receive ISO 13485 Certification
    FDA Breakthrough Device Designation Given to MI Transcatheter Heart Pump
    Contract Pharma

    Latest Breaking News From Contract Pharma

    High Purity New England Bolsters Biopharma Solutions Services
    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply
    CatSci Opens New Site in UK
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Inahsi Naturals Achieves EU Compliance
    Biden Prioritizes PPP Relief for the Beauty Industry
    Christie Brinkley Joins SBLA Beauty
    Happi

    Latest Breaking News From Happi

    Sephora To Open More Stores in 2021
    Clean Beauty Collective Supports EarthDay.org
    Freckle Pens Are Spot On!
    Ink World

    Latest Breaking News From Ink World

    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Lowe-Martin Adds 2 KODAK NEXFINITY Digital Presses
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    UFlex adds capacity in packaging films
    CEC expands into labels and packaging with Heidelberg
    ABG delivers Digicon Series 3 to UK printer
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Mexico City Single-Use Plastics Ban Leads to Tampon Shortage
    Believe Diapers Launch in U.S.
    Forbes Ranks Rockline Among Best U.S. Employers
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Kaia Health Unveils Next-Gen Complete MSK Care Solutions
    First Implantation of CTL Amedica's Minimally Invasive Flex Tower
    NuVasive Nabs Simplify Medical for $150M
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    RFID Locks Market to Reach $9.93 Billion by 2027: Allied Market Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login